Abstract:
Introduction.
Stroke is a rare disease in children and adolescents, with
an incidence of 2-13/100.000 children, and in the
prenatal period - 1: 4000 of live births. Studies of stroke
immune markers have become current.
Purpose.
Assessment of endoglin (CD105) in ischemic stroke (IS)
in children to determine its role in early diagnosis and
predictive factors of the disease.
Material and methods.
In 2017 − 2019 in the Republic of Moldova was carried
out a prospective study on a sample of 53 children with
IS (study sample, SS), investigated by ELISA in the acute
phase of the process determining the serum levels of
endoglin (CD105). At the same time, this marker was
appreciated in 53 "practically healthy" children (control
sample, CS).
Results. In SS statistically significant endoglin values were
found to be significantly lower than in CS (F = 84.812,
p<0.001), maximum values (4.02 ng/ml) and minimum
values (1.88 ng/ml). The mean level of endoglin, 2.06 ±
0.012 ng / ml in SS, does not exceed the level of 2.23
ng/ml, while in CS, the mean value of endoglin was 2.51 ±
0.071 ng/ml, has the maximum value of 4.02 ng/ml.
Conclusions.
In acute IS in children there is a significant decrease in
serum endoglin, signifying its role as a biomarker of
stroke and the need for therapeutic corrections indicated
in cerebral ischemic processes. Experimental and clinical
research on biomarkers promotes new discoveries in this
field, to improve the diagnosis and treatment of IS in
children.
Description:
Nicolae Testemițanu State University of Medicine and Pharmacy,
PHMI Institute of Mother and Child,
National Epilepsy Center, Chisinau, Republic of Moldova
